Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
Erwei ZengWei HeArvid SjölanderJenny BergqvistFang FangKamila CzenePublished in: Journal of the National Cancer Institute (2024)
Familial adversity is associated with a higher risk of adjuvant hormone therapy discontinuation and breast cancer-specific mortality. Family-related factors identified in our study may help identify high-risk patients for interventions to prevent treatment discontinuation and subsequently improve breast cancer outcomes.
Keyphrases
- end stage renal disease
- early stage
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early onset
- early life
- physical activity
- type diabetes
- cardiovascular events
- stem cells
- metabolic syndrome
- mesenchymal stem cells
- young adults
- patient reported outcomes
- adipose tissue
- combination therapy
- replacement therapy
- coronary artery disease